ArticleJournal of neuro-oncology2018
Oscillatory brain activity associates with neuroligin-3 expression and predicts progression free survival in patients with diffuse glioma.
Article in Journal of neuro-oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 46 citations in OpenAlex.
- Leveraging neuroscience imaging and electrophysiological assessments to decode neuron-glioma interactions.Neuro-oncology advances · 2026Review
- The influence of neuro-tumor interactions on tumorigenesis and therapeutic response.Experimental hematology & oncology · 2026Review
- Multiscale network perspectives on glioma: from tumour biology to symptoms, survival and treatment.Nature reviews. Neurology · 2026Review
- Patient-Centered Management of Brain Tumor-Related Epilepsy.Current neurology and neuroscience reports · 2024Review
- Symptom networks in glioma patients: understanding the multidimensionality of symptoms and quality of life.Journal of cancer survivorship : research and practice · 2024Article
- The relationship between pathological brain activity and functional network connectivity in glioma patients.Journal of neuro-oncology · 2024Article
- Brain tumor-related epilepsy management: A Society for Neuro-oncology (SNO) consensus review on current management.Neuro-oncology · 2024Review
- Molecular diversity in isocitrate dehydrogenase-wild-type glioblastoma.Brain communications · 2024Review
- Multiscale network neuroscience in neuro-oncology: How tumors, brain networks, and behavior connect across scales.Neuro-oncology practice · 2023Review
- Progress in cancer neuroscience.MedComm · 2023Review
- Neuromodulation for Brain Tumors: Myth or Reality? A Narrative Review.International journal of molecular sciences · 2023Review
- Considerations for modelling diffuse high-grade gliomas and developing clinically relevant therapies.Cancer metastasis reviews · 2023Review
- The neuroscience of cancer.Nature · 2023Review
- Article
- Cancer meets neuroscience: the association between glioma occurrence and intrinsic brain features.Brain : a journal of neurology · 2023Article
- The distribution of neuroligin4, an autism-related postsynaptic molecule, in the human brain.Molecular brain · 2023Article
- Brain network mapping and glioma pathophysiology.Brain communications · 2023Review
- Comparing individual and group-level simulated neurophysiological brain connectivity using the Jansen and Rit neural mass model.Network neuroscience (Cambridge, Mass.) · 2023Article
- Regional healthy brain activity, glioma occurrence and symptomatology.Brain : a journal of neurology · 2022Article
- The dark side of synaptic proteins in tumours.British journal of cancer · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 3 countries.
Funding
Abstract
introductionDiffuse gliomas have local and global effects on neurophysiological brain functioning, which are often seen as 'passive' consequences of the tumor. However, seminal preclinical work has shown a prominent role for neuronal activity in glioma growth: mediated by neuroligin-3 (NLGN3), increased neuronal activity causes faster glioma growth. It is unclear whether the same holds true in patients. Here, we investigate whether lower levels of oscillatory brain activity relate to lower NLGN3 expression and predict longer progression free survival (PFS) in diffuse glioma patients.
methodsTwenty-four newly diagnosed patients with diffuse glioma underwent magnetoencephalography and subsequent tumor resection. Oscillatory brain activity was approximated by calculating broadband power (0.5-48 Hz) of the magnetoencephalography. NLGN3 expression in glioma tissue was semi-quantitatively assessed by immunohistochemistry. Peritumor and global oscillatory brain activity was then compared between different levels of NLGN3 expression with Kruskal-Wallis tests. Cox proportional hazards analyses were performed to estimate the predictive value of oscillatory brain activity for PFS.
resultsPatients with low expression of NLGN3 had lower levels of global oscillatory brain activity than patients with higher NLGN3 expression (P < 0.001). Moreover, lower peritumor (hazard ratio 2.17, P = 0.008) and global oscillatory brain activity (hazard ratio 2.10, P = 0.008) predicted longer PFS.
conclusionsLower levels of peritumor and global oscillatory brain activity are related to lower NLGN3 expression and longer PFS, corroborating preclinical research. This study highlights the important interplay between macroscopically measured brain activity and glioma progression, and may lead to new therapeutic interventions in diffuse glioma patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.